JPH01246224A - Remedy for dementia - Google Patents

Abstract

PURPOSE:To provide a remedy for dementia having extremely low toxicity and high safety and composed of TOKI-SHAKUYAKU-SAN known as a Chinese herb drug. CONSTITUTION:The objective remedy for dementia is effective in promoting the synthesis of nicotineacethylcholine receptor and the synthesis of norepinephrine in cerebral cortex and remedying dementia, and is composed of a solution of TOKI-SHAKUYAKU-SAN which is a drug applied to various diseases such as cold constitution, anemia and stomach ache. Dried powdery extract of TOKI-SHAKUYAKU-SAN can be prepared by extracting 3-8 pts.wt. of SHAKUYAKU (root of Paeonia albiflora), 2-6 pts.wt. of JUTSU (rhizome of Atractylodes lancea), 2-8 pts.wt. of TAKUSHA (bulb of Alisma plantago- aquatica), 2-6 pts.wt. of BUKURYO (sclerotium of Poria cocos), 2-5 pts.wt. of SENKYU (rhizome of Cnidium officinale) and 2-5 pts.wt. of TOKI (root of Angelica acutiloba) with about 10 times volume of hot water, filtering the extracted liquid an drying the filtrate. The powder is converted into a drug preparation by conventional method to obtain the objective remedy for dementia.

Description

[Detailed description of the invention] [Industrial application field] The present invention relates to an anti-dementia agent.

In recent years, with changes in the population composition of Japan, medial nerve disorders in the elderly, particularly dementia, have become a socially important problem.

Recently, there have been reports pointing out abnormalities in receptors and neurotransmitters in the cerebral cortex regarding dementia, and various therapeutic drugs have been studied and developed for this disease, but there are still no drugs with excellent efficacy. It has not been escalated.

[Means for Solving the Problems] The present inventors believe that receptors such as nicodine acetylcholine receptors and norepinephrine in the cerebral cortex cause dementia.
Focusing on the decrease in the concentration of neurotransmitters such as ne), we believe that dementia can be treated by promoting the synthesis of receptors and neurotransmitters in the cerebral cortex, and have conducted intensive research on various Chinese herbal prescriptions. As a result, they discovered that Zunawara Tokishuonwara San, a Chinese herbal medicine prescription consisting of Tsunayaku, Norin, Sawatan, Kessei, Yoshuun, and Toki, has an anti-dementia effect, leading to the completion of the present invention. .

Since the present invention is based on this knowledge, we have developed an anti-dementia drug (hereinafter referred to as the anti-dementia drug of the present invention).

).

The anti-dementia agent of the present invention has its component herbal medicines, dosage, extraction method, etc. described in the classic Chinese herbal prescription, Kinba Yoro, and is used for various diseases such as sensitivity to cold, anemia, and abdominal pain. It was completely unknown until now that it had a therapeutic effect on dementia.

The anti-dementia agent of the present invention is based on the classical medicine,
, 4g of sawa, 4g of katsurei, 3g of yosun, 3g of toki for 220d
It can be decoctioned with water and taken in three doses as an anti-dementia drug, but in order to make it easier to take and more convenient to carry, a herbal medicine extract preparation is used as an anti-dementia drug. It can also be used.

For example, 3 to 8 parts by weight of Xunyaku, 2 to 6 parts by weight of JIt, 2 to 8 parts by weight of Zawatan, 2 to 6 parts by weight of Keili, 2 to 5 parts by weight of Yoxun, and 2 to 5 parts by weight of Danggui in IO times the amount. The extract obtained by hot extraction with a certain amount of water is filtered and dried to obtain a powder of Dangguixun medicinal powder, which is an anti-dementia agent. By adding adjuvants and the like, it can be made into preparations such as powders, granules, tablets, capsules, etc. according to conventional methods for manufacturing preparations.

A specific example of the production of the anti-dementia agent of the present invention is as follows.

Specific examples: Xun Yao 4g, Aoara 49, Zawatan 49, Kei Ling 49, Yochi 39,
Add 10 times the amount to 3g of mixed herbal medicine, or 220ffi (
! of water was added and extracted by heating at 100°C for 1 hour, and the resulting extract was filtered and spray-dried to obtain a dry extract powder with a weight of 3.89.

Next, the effectiveness of the anti-dementia agent of the present invention in the treatment of dementia will be explained using experimental examples.

Experimental Example 1 From day 22 after birth, the dried extract powder obtained in the specific example was administered to SD rats at a rate of 500~/kq together with drinking water for one week. The control group received drinking water only. One week later, the rats were sacrificed, the brain was removed, and the cerebral cortex was homogenized to determine the concentration of nicotine acetylcholine receptors (hereinafter referred to as nAchRs) and norepinephrine (hereinafter referred to as NE) in the brain tissue. was measured. The results are shown in Table 1.

Table 1 Experimental Example 2 The nAchRs amount was measured in the same manner as in Experimental Example 1 except that the administration was carried out for 2 weeks from 22 days after birth. The result was 182 ± 22 fM/IIg in the control group, whereas the dry extract powder administration In the group, it was 354±18 fM/149.

From the above results, it was confirmed that the dried extract powder obtained in the specific example promoted the synthesis of nAchRs and NE in the cerebral cortex, and was confirmed to be effective as an anti-dementia agent.

The acute toxicity test for oral administration of the anti-dementia agent of the present invention was conducted using ddY male mice and Wistar mice.
When the test was carried out using a strain of male rats, the dry extract powder of the anti-dementia agent of the present invention obtained in the specific example did not cause death even when administered orally at a dose of 15 g/&9 (dose limit).

Thus, the anti-dementia agent of the present invention has extremely low toxicity and high safety. Furthermore, considering that Tokishakuyakusan has been used as a medicinal medicine since ancient times up to the present, it is clear that it has few side effects. Considering the above experimental data and acute toxicity test results, the effective dose of the anti-dementia agent of the present invention varies depending on the age, weight, and severity of the disease of the patient, but is usually an adult dose of dry extract powder. It is considered appropriate to take 1-toir per day divided into 3 doses per day depending on the symptoms.

Next, the present invention will be described in more detail by showing examples, but the present invention is not limited thereto.

Example I 200 g of dry extract powder produced according to the above specific example was combined with 89 g of lactose and magnesium stearate! 9 and press this mixture into tablets using a single-shot key press to form tablets with a diameter of 20 mm.
A slug tablet having a weight of about 2.39 myS was prepared, which was pulverized in an onrator, sized, and sieved to obtain good granules with particles of 20 to 50 mesh.

This granule is available in an equivalent amount of 0.5 to 459 (1) depending on the symptoms.
0.3 as dry extract powder weight of the anti-dementia agent of the present invention
(equivalent to 4 to 3.10 y) three times a day.

Example 2 200 g of the dry extract powder produced according to the above specific example was mixed with 209 microcrystalline cellulose and 5 g of magnesium stearate, and this mixture was compressed using a single-shot tablet machine to form tablets with a diameter of 7 mm and a weight of 225 ~. Tablets were manufactured. This tablet 1
The tablet contains 200% dry extract powder of the anti-dementia agent of the present invention.
~contains.

Take 2 to 16 tablets of the same amount three times a day depending on your symptoms.

Example 3 Dry extract powder 5007f produced according to the above specific example
i9 was filled into hard capsules. This capsule is taken in 2 to 20 capsules three times a day, depending on the symptoms.

Claims (1)

[Claims] Anti-dementia drug consisting of Tokishakuyakusan